Alternative Boxwood

Note
Integrative therapies should not replace antiretroviral therapy (ART) in HIV patients. Patients should consult their healthcare providers before taking any herbs or supplements because they may interact with treatment.
In particular, patients should not take St. John’s wort because it may interact with HIV treatment.

Unclear or conflicting scientific evidence

Boxwood

Trials have been conducted for SPV30 (extract of boxwood, Arkopharma, France) to evaluate its potential effectiveness for HIV/AIDS.

Rigorous clinical study is needed to confirm these early study results.

  1. Avoid if allergic or hypersensitive to boxwood, its constituents, or any plants in the Buxaceae family.
  2. Avoid if pregnant or breast feeding.

Selected References
AIDS.org. www.aids.org. Accessed March 29, 2009.
American Foundation for AIDS Research (amfAR). www.amfar.org. Accessed March 29, 2009.
Centers for Disease Control and Prevention (CDC). www.cdc.gov. Accessed March 29, 2009.
Elizabeth Glaser Pediatric AIDS Foundation. www.pedaids.org. Accessed March 29, 2009.
Halperin DT, Steiner MJ, Cassell MM, et al. The time has come for common ground on preventing sexual transmission of HIV. Lancet. 2004 Nov 27-Dec 3;364(9449):1913-5.
Loutfy MR, Antoniou T, Shen S, et al. Virologic and immunologic impact and durability of enfuvirtide-basedantiretroviraltherapy in HIV-infected treatment-experienced patients in a clinical setting. HIV Clin Trials. 2007Jan-Feb;8(1):36-44.
National Institute of Allergy and Infectious Diseases (NIAD). www.niaid.nih.gov. Accessed March 29, 2009.
Natural Standard: The Authority on Integrative Medicine. www.naturalstandard.com. Copyright © 2009. Accessed March 29, 2009.
Rigopoulos D, Gregoriou S, Paparizos V, et al. AIDS in pregnancy, part II: Treatment in the era of highly active antiretroviral therapy and management of obstetric, anesthetic, and pediatric issues. Skinmed. 2007
Mar-Apr;6(2):79-84.
The Body: The Complete HIV/AIDS Resource. www.thebody.com. Accessed March 29, 2009.
U.S. Food and Drug Administration (FDA). www.fda.gov. Accessed March 29, 2009.
Vrouenraets SM, Wit FW, van Tongeren J, et al. Efavirenz: a review. Expert Opin Pharmacother. 2007 Apr;8(6):851-71.